Icure Pharmaceutical Incorporation reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was KRW 348.03 million compared to KRW 2,038.24 million a year ago. Net loss was KRW 2,255.26 million compared to KRW 5,712.87 million a year ago. Basic loss per share from continuing operations was KRW 60 compared to KRW 250.8333 a year ago. Diluted loss per share from continuing operations was KRW 60 compared to KRW 250.8333 a year ago. Basic loss per share was KRW 60 compared to KRW 301 a year ago.
For the nine months, sales was KRW 1,472.92 million compared to KRW 2,343.4 million a year ago. Net loss was KRW 14,940.44 million compared to KRW 22,029.06 million a year ago. Basic loss per share from continuing operations was KRW 398 compared to KRW 968.3333 a year ago. Diluted loss per share from continuing operations was KRW 398 compared to KRW 968.3333 a year ago. Basic loss per share was KRW 398 compared to KRW 1,162 a year ago.